^
Association details:
| Biomarker: | VEGFA elevation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Rapid decrease in serum VEGF-A levels may be a worse prognostic biomarker for patients with platinum-resistant recurrent ovarian cancer treated with bevacizumab and gemcitabine
Published date:
04/13/2020
Excerpt:
Platinum-resistant ovarian cancer patients treated with Bev-Gem therapy...The rapid decrease in VEGF-A levels and the resultant increase in serum VEGF-B levels might be associated with an unfavorable clinical outcome.
Secondary therapy:
gemcitabine
DOI:
10.1007/s00280-020-04070-8
